Radioimmunotherapy with radretumab in patients with relapsed hematologic malignancies

Journal of Nuclear Medicine

Volumn 53, Issue 6, 2012, Pages 922-927

  Erba, Paola A ^a,b   Sollini, Martina ^a   Orciuolo, Enrico ^a   Traino, Claudio ^c   Petrini, Mario ^a   Paganelli, Giovanni ^d   Bombardieri, Emilio ^e   Grana, Chiara ^d   Giovannoni, Leonardo ^f   Neri, Dario ^g   Menssen, Hans D ^f   Mariani, Giuliano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b S MARIA NUOVA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f Philogen SpA   (Italy)

^g ETH ZURICH   (Switzerland)

Author keywords

Dosimetry; EDB fibronectin; Lymphoma; Radioimmunotherapy; Radretumab

Indexed keywords

RADRETUMAB;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CLINICAL ARTICLE; DOSIMETRY; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG UPTAKE; DRUG USE; FEMALE; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LEUKEMIA; LEUKOPENIA; LYMPHOMA; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REPEATED DRUG DOSE; RISK BENEFIT ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; CLINICAL TRIALS AS TOPIC; FEMALE; FIBRONECTINS; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RADIOIMMUNOTHERAPY; RECURRENCE;

EID: 84861894823     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.101006     Document Type: Article

References (20)

1. Pini A, Viti F, Santucci A, et al. Design and use of a phage display library: human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem. 1998;273:21769-21776. (Pubitemid 28405353)
2. Menrad A, Menssen HD. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin Ther Targets. 2005;9:491-500. (Pubitemid 40883149)
3. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer. 2006;118:1331-1339.
4. Borsi L, Balza E, Bestagno M, et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer. 2002;102:75-85.
5. Berndorff D, Borkowski S, Sieger S, et al. Radioimmunotherapy of solid tumors by targeting extra domain B fibronectin: identification of the best-suited radio-immunoconjugate. Clin Cancer Res. 2005;11:7053s-7063s. (Pubitemid 41428704)
6. Schliemann C, Palumbo A, Zuberbühler K, et al. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood. 2009;113:2275-2283.
7. 131I-L19SIP radio-immunotherapy in Hodgkin lymphoma patients. Blood. 2009;113:2265-2274.
8. Hunter WM, Greenwood FC. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature. 1962;194:495-496.
9. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586. (Pubitemid 350002966)
10. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467-1473. (Pubitemid 44264086)
11. Santimaria M, Moscatelli G, Viale GL, et al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003;9:571-579. (Pubitemid 36182586)
12. Czabanka M, Parmaksiz G, Bayerl SH, et al. Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies. Eur J Cancer. 2011;47:1276-1284.
13. Fisher RI, KaminskiMS,Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005;23:7565-7573. (Pubitemid 46291820)
14. Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804-1810. (Pubitemid 46668544)
15. Schnell R, Dietlein M, Schomäcker K, et al. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's lymphoma. Onkologie. 2008;31:49-51. (Pubitemid 351252941)
16. Koral KF, Dewaraja Y, Clarke LA, et al. Tumor-absorbed-dose estimates versus response in tositumomab therapy of previously untreated patients with follicular non-Hodgkin's lymphoma: preliminary report. Cancer Biother Radiopharm. 2000;15:347-355.
17. 90Y-ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non- Hodgkin lymphoma. Mol Imaging Biol. 2010;12:198-203.
18. 131I-tositumomab in clinical practice. J Nucl Med. 2007;48:1767-1776.
19. 90Y-ibritumomab tiuxetan as consolidation of first remission in advanced-stage follicular lymphoma: results from the international phase 3 first-line indolent trial. J Nucl Med. 2009;50:1837-1843.
20. 131I-tositumomab. J Nucl Med. 2010;51:1878-1884.